

# Andrew Haydon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4612932/publications.pdf>

Version: 2024-02-01

69  
papers

7,169  
citations

201674

27  
h-index

138484

58  
g-index

70  
all docs

70  
docs citations

70  
times ranked

9237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	13.7	236
2	Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial. <i>Cancer Prevention Research</i> , 2022, 15, 365-375.	1.5	3
3	Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial. <i>Cancer Epidemiology</i> , 2022, 79, 102173.	1.9	0
4	Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies. <i>British Journal of Cancer</i> , 2022, 127, 1735-1743.	6.4	10
5	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, e425-e430.	2.6	15
6	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
7	The acceleration of ageing in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 343-351.	1.0	14
8	Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 2759-2773.	5.1	7
9	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946.	1.6	1
10	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021, 7, 744.	7.1	110
11	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
12	Prediagnosis alcohol intake and metachronous cancer risk in cancer survivors: A prospective cohort study. <i>International Journal of Cancer</i> , 2021, 149, 827-838.	5.1	2
13	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	8.4	88
14	Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. <i>Oncologist</i> , 2021, 26, 461-464.	3.7	1
15	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021, 22, 836-847.	10.7	104
16	Factors Explaining Socio-Economic Inequalities in Survival from Colon Cancer: A Causal Mediation Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1807-1815.	2.5	4
17	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	2.8	12
18	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021, 91, 3-13.	0.7	7

#	ARTICLE	IF	CITATIONS
19	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , 2021, 22, e343-e344.	10.7	2
20	783 Lifetime alcohol intake and stomach cancer risk: a pooled analysis of two prospective cohort studies. <i>International Journal of Epidemiology</i> , 2021, 50, .	1.9	0
21	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
22	Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa107.	2.9	2
23	383 – Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695. , 2021, 9, A417-A417.		2
24	341 – A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC). , 2021, 9, A367-A367.		0
25	547 – CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma. , 2021, 9, A577-A577.		1
26	340 – A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC). , 2021, 9, A366-A366.		0
27	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	3.3	51
28	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	7.1	287
29	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. , 2020, 8, e001681.		57
30	Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 1282-1285.	0.8	9
31	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	27.0	256
32	Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. <i>Australasian Journal of Dermatology</i> , 2020, 61, 203-209.	0.7	4
33	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 150-156.	0.8	11
34	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2140-2150.	1.6	68
35	Caution in the age of optimism; a salient lesson in advanced melanoma. <i>Annals of Translational Medicine</i> , 2020, 8, 720-720.	1.7	1
36	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	2.8	64

#	ARTICLE	IF	CITATIONS
37	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	10.7	50
38	Reply to E. Hindi and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	1.6	1
39	The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. <i>BMJ Open</i> , 2019, 9, e031434.	1.9	27
40	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28.	0.5	10
41	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	12.1	234
42	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
43	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	27.0	1,441
44	Concordance of somatic mutational profile in multiple primary melanomas. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 592-603.	3.3	1
45	Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. <i>International Journal of Surgery</i> , 2018, 51, 71-75.	2.7	6
46	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2018, 19, 562-578.	10.7	133
47	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 90-94.	1.3	8
48	Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. <i>International Journal of Cancer</i> , 2018, 142, 238-250.	5.1	83
49	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600E Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	1.6	226
50	Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. <i>British Journal of Cancer</i> , 2018, 118, 1289-1295.	6.4	13
51	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9590-9590.	1.6	9
52	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9591-9591.	1.6	8
53	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	6.4	91
54	P2.02-052 Does Delay from Diagnosis to Start of Radiotherapy, or Modified Comorbidity Score Impact Survival in Curatively Treated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S879-S880.	1.1	0

#	ARTICLE	IF	CITATIONS
55	Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	27.0	1,192
56	Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. <i>British Journal of Cancer</i> , 2017, 117, 1026-1035.	6.4	46
57	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017, 117, 921-924.	6.4	81
58	Metastatic pathways in patients with cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 13-27.	3.3	38
59	Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 361-368.	1.3	23
60	Optimizing combination dabrafenib and trametinib therapy in <i>BRAF</i> mutation- $\epsilon$ positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 5-12.	1.1	22
61	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the <i>KRAS</i> G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	1.6	52
62	A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1014-1023.	3.7	56
63	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	12.4	1,036
64	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> and <i>PI3KCA</i> wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	2.6	15
65	The Victorian Melanoma Service: A 20-year review of an Australian multidisciplinary cancer service. <i>Australasian Journal of Dermatology</i> , 2016, 57, 235-237.	0.7	3
66	Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX $\alpha$ , $\epsilon$ vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 507-518.	4.2	31
67	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2477-2484.	1.6	122
68	Investigation of the Safety of Irreversible Electroporation in Humans. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 611-621.	0.5	408
69	Inferior vena caval leiomyosarcoma in a patient with past bilateral retinoblastoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 181-183.	1.1	0